23. Gore ME, Szczylik C, Porta C et al. Safety and efficacy of sunitinib for metastatic
renal-cell carcinoma: an expanded-access trial. Lancet Oncol 2009; 10:
24. Ravaud A, Oudard S, Gravis-Mescam G et al. First-line sunitinib in type I and II
papillary renal cell carcinoma (PRCC): SUPAP, a phase II study of the French
Genito-Urinary Group (GETUG) and the Group of Early Phase trials (GEP). J Clin
Oncol 2009; 27: 5146 (Meeting Abstracts).
25. Molina AM, Feldman DR, Ginsberg MS et al. Phase II trial of sunitinib in patients
with metastatic non-clear cell renal cell carcinoma. Invest New Drugs 2010 Aug
14 [epub ahead of print].
26. Plimack ER, Jonasch E, Bekele BN et al. Sunitinib in papillary renal cell
carcinoma (pRCC): results from a single-arm phase II study. J Clin Oncol 2010;
28: 4604 (Meeting Abstracts).
27. Plimack ER, Jonasch E, Bekele BN et al. Sunitinib in non-clear cell renal cell
carcinoma (ncc-RCC): a phase II study. J Clin Oncol 2008; 26: 5112 (Meeting
28. Stadler WM, Figlin RA, Ernstoff MS et al. The Advanced Renal Cell Carcinoma
Sorafenib (ARCCS) expanded access trial: safety and efficacy in patients (pts)
with non-clear cell (NCC) renal cell carcinoma (RCC). J Clin Oncol 2007; 25:
5036. (Meeting Abstracts).
29. Dutcher J, de Souza P, McDermott D et al. Effect of temsirolimus versus
interferon-α on outcome of patients with advanced renal cell carcinoma of
different tumor histologies. Med Oncol 2009; 26: 202–209.
30. Dutcher J, Szczylik C, Tannir NM et al. Correlation of survival with tumor
histology, age, and prognostic risk group for previously untreated patients with
advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or
interferon-alpha (IFN). J Clin Oncol 2007; 25: 5033 (Meeting Abstracts).
31. Uemura H, Shinohara N, Yuasa T et al. A phase II study of sunitinib in Japanese
patients with metastatic renal cell carcinoma: insights into the treatment, efficacy
and safety. Jpn J Clin Oncol 2010; 40: 194–202.
32. Richards CJ, Je Y, Schutz FA et al. Incidence and risk of congestive heart failure
in patients with renal and nonrenal cell carcinoma treated with sunitinib. J Clin
Oncol 2011; 29: 3450–3456.
Annals of Oncology 23: 2114–2121, 2012
Published online 8 February 2012
Polymorphisms in the IL-13 and IL-4R genes are
associated with the development of renal cell carcinoma
H. Chu1,2,†, M. Wang2,3,†, F. Yan2,3,†, D. Zhong1,3, D. Shi2,3, L. Ma2,3, X. Pan4, C. Qin5, C. Yin5
& Z. Zhang1,2,3*
1State Key Laboratory of Reproductive Medicine, Institute of Toxicology, Nanjing Medical University, Nanjing;2Department of Molecular & Genetic Toxicology, the Key
Laboratory of Modern Toxicology of Ministry of Education, School of Public Health, Nanjing Medical University, Nanjing;3Department of Occupational Medicine and
Environmental Health, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Cancer Center, Nanjing Medical University, Nanjing;4Department of
Core Laboratory, the Third Affiliated Hospital of Nanjing Medical University, Yizheng;5Department of Urology, the First Affiliated Hospital of Nanjing Medical University,
Received 23 October 2011; revised 27 November 2011; accepted 5 December 2011
Background: Cytokines are the important modulators that bind to their relevant receptors in response to some stimuli
to mediate the homeostasis. It has been suggested that the imbalance of immune system of the host might affect the
generation of diseases, including cancers.
Patients and methods: We investigated the association between six functional polymorphisms of IL-4, IL-13, and IL-
4R genes and susceptibility to renal cell cancer in a hospital-based study, including 620 renal cell carcinoma (RCC)
patients and 623 controls. Logistic regression model was used to assess the genetic effects on the development of
Results: Overall, individuals with IL-4R Ile50Val CT/TT genotypes had a 0.34-fold significantly decreased RCC risk
(CT/TT versus CC), and the T variant allele was associated with a decreased risk of RCC in a dose–response manner
(Ptrend= 0.009). In addition, we also observed that IL-13 C-1055T and Arg130Gln polymorphisms could decrease the
risk of RCC [TT versus CC/CT: odds ratio = 0.36, 95% confidence interval (CI)= 0.16–0.78; AA versus GG/GA: 0.66,
0.44–0.97, respectively]. Furthermore, a multiplicative interaction association between the combined IL-4R Ile50Val and
IL-13 C-1055T genotypes was observed to decrease the risk of RCC (P =0.036).
Conclusion: IL-13 and IL-4R may play an important role in the etiology of RCC.
Key words: inflammation gene, molecular epidemiology, polymorphism, renal cell cancer, susceptibility
†These authors contributed equally to this work.
*Correspondence to: Dr Z. Zhang, State Key Laboratory of Reproductive Medicine,
Institute of Toxicology, Nanjing Medical University, 140 Hanzhong Road, Nanjing
210029, China. Tel: +86-25-86862926; Fax: +86-25-86527613;
Annals of Oncology
© The Author 2012. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
All rights reserved. For permissions, please email: firstname.lastname@example.org
by guest on January 2, 2016
18. Wood N, Whitters MJ, Jacobson BA et al.. Enhanced interleukin (IL)-13 responses
in mice lacking IL-13 receptor alpha 2 J Exp Med 2003; 197: 703–709.
19. Obiri NI, Husain SR, Debinski W, Puri RKInterleukin 13 inhibits growth of human
renal cell carcinoma cells independently of the p140 interleukin 4 receptor chain
Clin Cancer Res 1996; 2: 1743–1749.
20. Holgate STThe epidemic of allergy and asthma Nature 1999; 402: B2–B4.
21. Wills-Karp M, Luyimbazi J, Xu X et al.. Interleukin-13: central mediator of allergic
asthma Science 1998; 282: 2258–2261.
22. Noguchi E, Nukaga-Nishio Y, Jian Z et al.. Haplotypes of the 5’ region of the IL-4
gene and SNPs in the intergene sequence between the IL-4 and IL-13 genes are
associated with atopic asthma Hum Immunol 2001; 62: 1251–1257.
23. Zhu J, Ju X, Yan F et al.. Association of IL-4 -590 T>C polymorphism and risk
of renal cell carcinoma in a Chinese population Int J Immunogenet 2010; 37:
24. Kazemi Arababadi MInterleukin-4 gene polymorphisms in type 2 diabetic patients
with nephropathy Iran J Kidney Dis 2010; 4: 302–306.
25. Cameron L, Webster RB, Strempel JM et al.. Th2 cell-selective enhancement of
human IL13 transcription by IL13-1112C>T, a polymorphism associated with
allergic inflammation J Immunol 2006; 177: 8633–8642.
26. Graves PE, Kabesch M, Halonen M et al.. A cluster of seven tightly linked
polymorphisms in the IL-13 gene is associated with total serum IgE levels in three
populations of white children J Allergy Clin Immunol 2000; 105: 506–513.
27. Liu X, Beaty TH, Deindl P et al.. Associations between total serum IgE levels and
the 6 potentially functional variants within the genes IL4, IL13, and IL4RA in
German children: the German Multicenter Atopy Study J Allergy Clin Immunol
2003; 112: 382–388.
28. Ober C, Tsalenko A, Parry R, Cox NJA second-generation genomewide screen for
asthma-susceptibility alleles in a founder population Am J Hum Genet 2000; 67:
29. Ivansson EL, Gustavsson IM, Magnusson JJ et al.. Variants of chemokine
receptor 2 and interleukin 4 receptor, but not interleukin 10 or Fas ligand,
increase risk of cervical cancer Int J Cancer 2007; 121: 2451–2457.
30. Qin C, Cao Q, Ju X et al.. The polymorphisms in the VHL and HIF1A genes are
associated with the prognosis but not the development of renal cell carcinoma
Ann Oncol 2011; 23: 981–989.
31. Hochberg Y, Benjamini YMore powerful procedures for multiple significance
testing Stat Med 1990; 9: 811–818.
32. Wills-Karp M, Finkelman FDUntangling the complex web of IL-4- and IL-13-
mediated signaling pathways Sci Signal 2008; 1: pe55.
33. Hosoyama T, Aslam MI, Abraham J et al.. IL-4R drives dedifferentiation,
mitogenesis, and metastasis in rhabdomyosarcoma Clin Cancer Res 2011; 17:
34. Terabe M, Matsui S, Noben-Trauth N et al.. NKT cell-mediated repression of
tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway Nat Immunol
2000; 1: 515–520.
35. Berzofsky JA, Terabe MA novel immunoregulatory axis of NKT cell subsets
regulating tumor immunity Cancer Immunol Immunother 2008; 57: 1679–1683.
36. MalekZadeh K, Nikbakht M, Sadeghi IA et al.. Overexpression of IL-13 in patients
with bladder cancer Cancer Invest 2010; 28: 201–207.
37. Mitsuyasu H, Izuhara K, Mao XQ et al.. Ile50Val variant of IL4R alpha upregulates
IgE synthesis and associates with atopic asthma Nat Genet 1998; 19: 119–120.
38. Hershey GK, Friedrich MF, Esswein LA et al.. The association of atopy with a
gain-of-function mutation in the alpha subunit of the interleukin-4 receptor N
Engl J Med 1997; 337: 1720–1725.
39. Kruse S, Japha T, Tedner M et al.. The polymorphisms S503P and Q576R in the
interleukin-4 receptor alpha gene are associated with atopy and influence the
signal transduction Immunology 1999; 96: 365–371.
40. Schwartzbaum J, Ahlbom A, Malmer B et al.. Polymorphisms associated with
asthma are inversely related to glioblastoma multiforme Cancer Res 2005; 65:
41. Nedoszytko B, Niedoszytko M, Lange M et al.. Interleukin-13 promoter gene
polymorphism-1112C/T is associated with the systemic form of mastocytosis
Allergy 2009; 64: 287–294.
42. Ruan Z, Zhao Y, Yan L et al.. Single nucleotide polymorphisms in IL-4Ra, IL-13
and STAT6 genes occurs in brain glioma Front Biosci (Elite Ed) 2011; 3: 33–45.
43. Cao Q, Qin C, Meng X et al.. Genetic polymorphisms in APE1 are associated
with renal cell carcinoma risk in a Chinese population Mol Carcinog 2011; 50:
44. Hunt PJ, Marshall SE, Weetman AP et al.. Cytokine gene polymorphisms in
autoimmune thyroid disease J Clin Endocrinol Metab 2000; 85: 1984–1988.
45. Rosenwasser LJ, Klemm DJ, Dresback JK et al.. Promoter polymorphisms in the
chromosome 5 gene cluster in asthma and atopy Clin Exp Allergy 1995;
25Suppl 274–78. discussion 95–176.
46. Oral HB, Dilek K, Ozcimen AA et al.. Interleukin-4 gene polymorphisms confer
Behcet’s disease in Turkish population Scand J Immunol 2011; 73: 594–601.
Annals of Oncology
Volume 23 | No. 8 | August 2012 doi:10.1093/annonc/mdr607 |
by guest on January 2, 2016